Article

Transaction in own shares

Monday, September 20, 2021 - 6:08pm

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Arix intends to retain the purchased shares in treasury.
  • Following settlement of the above purchase, Arix will have 129,962,800 ordinary shares of 0.001 pence each in issue (excluding 5,646,853 ordinary shares of 0.001p each held in treasury).
  • In accordance with Article 5(1)(b) of Regulation (EU) No.

Healthily and Best Practice AI publish world's first AI Explainability Statement reviewed by the ICO

Monday, September 20, 2021 - 12:36pm

LONDON, Sept. 20, 2021 /PRNewswire/ -- One of the world's leading AI smart symptom checkers has taken the groundbreaking decision to publish a statement explaining how it works.

Key Points: 
  • The Healthily AI Explainability Statement explains how Healthily uses AI in its app including why AI is being used, how the AI system was designed and how it operates.
  • Healthily, a leading consumer digital healthcare company, worked with a team from the AI advisory firm, Best Practice AI, the international law firm Simmons & Simmons, and Jacob Turner from Fountain Court Chambers to create the first AI Explainability Statement in the sector.
  • A spokesperson for the ICO confirmed:
    "In preparing its Explainability Statement, Healthily received feedback from the UK's data protection regulator, the Information Commissioner's Office (ICO) and the published Statement reflects that input.
  • To learn more about how Best Practice AI, Simmons & Simmons LLP, and Jacob Turner from Fountain Court Chambers built the AI Explainability Statement, please contact us below.

Transaction in own shares

Friday, September 17, 2021 - 7:12pm

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Arix intends to retain the purchased shares in treasury.
  • Following settlement of the above purchase, Arix will have 129,996,800 ordinary shares of 0.001 pence each in issue (excluding 5,612,853 ordinary shares of 0.001p each held in treasury).
  • In accordance with Article 5(1)(b) of Regulation (EU) No.

Clinical Pilot Study Confirms the Accuracy and Effectiveness of Pixee Medical's Knee+ Solution Using Vuzix M400 Smart Glasses for Total Knee Arthroplasty

Friday, September 17, 2021 - 2:15pm

Pixee Medical has now shipped more than 100 Knee+ systems, which allow the surgeon to view the tibial and femur axis superimposed on the surgical field through smart glasses.

Key Points: 
  • Pixee Medical has now shipped more than 100 Knee+ systems, which allow the surgeon to view the tibial and femur axis superimposed on the surgical field through smart glasses.
  • "Pixee Medical's Knee+ Total Knee Arthroplasty product is a scalable solution that continues to meet the needs of surgeons and provides a cutting-edge technology that is easy to use.
  • Our attractive AR smart glasses-based product is affordable and does not require consumable management," commentedSbastien Henry, Founding President of Pixee Medical.
  • Vuzix is a leading supplier of Smart Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets.

Fuller, Smith & Turner PLC: Additional Listing

Friday, September 17, 2021 - 12:07pm

Application has been made to the UK Listing Authority and to the London Stock Exchange for admission to the Official List for a further issue of 993,205 'A' Ordinary Shares of 0.40 each.

Key Points: 
  • Application has been made to the UK Listing Authority and to the London Stock Exchange for admission to the Official List for a further issue of 993,205 'A' Ordinary Shares of 0.40 each.
  • It is expected that admission will become effective in the 'A' Ordinary Shares on or around the 20 September 2021.
  • Following Admission, the Company's issued share capital consists of 41,082,339 A Ordinary Shares of 40 pence each, 89,052,625 B Ordinary Shares of 4 pence each, and 13,466,013 C Ordinary Shares of 40 pence each, each carrying one vote.
  • Of this total, 1,264,646 A Ordinary Shares and 4,327,915 B Ordinary Shares are held in treasury.

Transaction in own shares

Thursday, September 16, 2021 - 6:05pm

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Arix intends to retain the purchased shares in treasury.
  • Following settlement of the above purchase, Arix will have 130,031,800 ordinary shares of 0.001 pence each in issue (excluding 5,577,853 ordinary shares of 0.001p each held in treasury).
  • In accordance with Article 5(1)(b) of Regulation (EU) No.

Avicanna Completes Registration and Commercial Export of its Evidence-Based CBD Dermacosmetics Brand, Pura Earth, in Ecuador

Thursday, September 16, 2021 - 12:30pm

TORONTO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has completed product registration and its first commercial export of its Pura Earth branded dermacosmetics products in Ecuador.

Key Points: 
  • In addition to the completed clinical trials all Pura Earth products are not tested on animals and are vegan.
  • The 3 cosmetic clinical studies were completed on Avicannas formulations targeting cosmetic factors associated with aging, acne-prone skin, and eczema-prone skin.
  • Intersive Moisturizing Cream: Oil-based formula uniquely marries CBD, colloidal oatmeal and hemp seed oil aimed at relieving skin redness 2,10.
  • Pura H&W/Pura Earth: these registered, clinically tested, cosmetic products include a portfolio of functional CBD consumer derma-cosmetic and topical products.

DGAP-News: Majorel Group Luxembourg S.A. : Majorel sets indicative price range and starts the offer period for planned private placement ahead of envisaged listing on Euronext Amsterdam

Thursday, September 16, 2021 - 8:04am

This publication constitutes neither an offer to sell nor a solicitation to buy securities.

Key Points: 
  • This publication constitutes neither an offer to sell nor a solicitation to buy securities.
  • This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons.
  • The Underwriters are acting exclusively for Majorel and the selling shareholders and no-one else in connection with the planned Private Placement.
  • 16.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.

Transaction in own shares

Wednesday, September 15, 2021 - 6:25pm

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Arix intends to retain the purchased shares in treasury.
  • Following settlement of the above purchase, Arix will have 130,066,800 ordinary shares of 0.001 pence each in issue (excluding 5,542,853 ordinary shares of 0.001p each held in treasury).
  • In accordance with Article 5(1)(b) of Regulation (EU) No.

DGAP-News: BRAIN Biotech AG resolves on a cash capital increase from authorised capital

Wednesday, September 15, 2021 - 5:08pm

The Management Board of BRAIN Biotech AG today has resolved to increase the company's share capital against cash contribution.

Key Points: 
  • The Management Board of BRAIN Biotech AG today has resolved to increase the company's share capital against cash contribution.
  • The company's share capital shall be increased against cash contribution by issuing new registered shares with no par value.
  • The share capital is to be increased through partial utilization of the existing authorized capital pursuant to Section 5(2) of the Company's Articles of Association (the "Capital Increase").
  • Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).